Credo Technology Group 주식 (NASDAQ: CRDO)

에 대한 최신 뉴스 Credo Technology Group (NASDAQ:CRDO) 주식

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

acciones sobrevendidas, acciones en tendencia

Equities

News

Markets

$BTC

CRDO

CRWD

MSTR

TSLA

화요일(4일) 미국 증시는 도널드 트럼프 대통령의 주요 무역 파트너에 대한 관세가 발효되면서 글로벌 무역 긴장이 심화됨에 따라 하락했다. 다우존스 산업평균지수는 1.55% 하락한 42,520.99포인트, S&amp;P 500 지수는 1.22% 하락한 5,778.15포인트를 기록했다. 나스닥 종합지수는 0.35% 하락한 18,285.16포인트로 조정 영역에 근접했다.

화요일 주목받은 주식: 스트레티지, 크라우드스트라이크, 베스트바이, 크레도 및 테슬라

Super Micro Computer, Inc. SMCI

Large Cap

Movers

Trading Ideas

DOCU

LULU

MRVL

PSTG

RBRK

ROKU

SMCI

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 크레도 테크놀로지 그룹 홀딩(NASDAQ:CRDO) 주식은 2분기 실적 발표 후 주가가 51.61% 급등하였으며, 여러 회사들이 주식에 대한 가격 예측을 상향 조정했다.

슈퍼 마이크로, 룰루레몬 및 로쿠 지난주 최고 성과를 보여준 11개 대형주 중 일부 (12월 2일-6일)

Credo Technology Group Holding Ltd

크레도 테크놀로지 그룹 홀딩스(NASDAQ:CRDO)의 주가는 월요일에 예상치를 크게 상회하는 2025회계연도 2분기 재무 실적을 발표한 후 화요일(3일) 급등하고 있다. 알아 두어야 할 내용은 다음과 같다.

크레도 테크놀로지 주가 48% 급등, 무슨 일일까?

Credo Technology Group Holding Ltd - Ordinary Shares

Cerrado Gold Inc

Amkor Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/04/b45051935/amkor-technology-reports-financial-results-for-the-first-quarter-2025"> from the quarter. </a>
The Details: Amkor reported quarterly earnings of nine cents per share, in line with the analyst consensus estimate. Quarterly revenue came in at $1.32 billion, which beat the $1.28 billion consensus estimate.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
&#8220;Amkor delivered first quarter results in line with expectations, with revenue of $1.32 billion and EPS of $0.09,&#8221; said Giel Rutten, Amkor&#8217;s CEO. 
&#8220;We are closely monitoring the evolving landscape with tariffs and trade regulations and potential impacts on our customers&#8217; supply chains. Our diversified global footprint and long-standing partnerships allow us to help our customers work through complexity and uncertainty,&#8221; Rutten added. 
Outlook: Amkor sees second-quarter earnings of between seven cents and 23 cents per share, versus the 15 cent estimate, and revenue in a range of $1.375 billion to $1.475 billion, versus the $1.33 billion estimate.  
AMKR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Amkor Technology stock was up 2.17% after-hours at $17.86 on Monday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

After-Hours Center

Tech

AMKR

Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates

General

ATOM

Atomera Incorporated Announces A Strategic Marketing Agreement With A Global Leader In Chip Fabrication Technology Aimed At Accelerating The Adoption Of Atomera's Mears Silicon Technology For Next-generation Technologies; Terms Not Disclosed

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 27.1%. Currently, NRG Energy has a market capitalization of $22.27 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $326.16 today based on a price of $109.36 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745873110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In NRG Energy 5 Years Ago Would Be Worth This Much Today

WIIM

TVGN

Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Overweight rating and announces Price Target of $104.

Price Target

Initiation

Analyst Ratings

VKTX

Cantor Fitzgerald Initiates Coverage On Viking Therapeutics with Overweight Rating, Announces Price Target of $104

NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a look at some of the key details <a href="https://www.benzinga.com/pressreleases/25/04/g45052384/nxp-semiconductors-reports-first-quarter-2025-results-announces-management-transition">from the report</a>.
Q1 Earnings: NXP reported first-quarter revenue of $2.84 billion, in line with analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a>, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported first-quarter adjusted earnings of $2.64 per share, beating analyst estimates of $2.58 per share.
Total revenue in the first quarter was down 9% on a year-over-year basis. The company said it generated $565 million in cash flow from operations, as well as free cash flow of $427 in the quarter.
&#8220;NXP delivered quarterly revenue of&nbsp;$2.84 billion, in-line with the midpoint of&nbsp;guidance. NXP&#8217;s&nbsp;first-quarter&nbsp;results and&nbsp;guidance&nbsp;for the&nbsp;second quarter&nbsp;underpin a cautious optimism that NXP continues to effectively navigate through a challenging set of market conditions,&#8221; said Kurt Sievers, president and CEO of NXP.
&#8220;We are operating in a very uncertain environment influenced by tariffs with volatile direct and indirect effects. Considering these external factors, we are redoubling our efforts to manage what is in our direct control, enabling NXP to drive solid profitability and earnings.&#8221;
Related Link: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45038044/top-wall-street-forecasters-revamp-nxp-semiconductors-expectations-ahead-of-q1-earnings">Top Wall Street Forecasters Revamp NXP Semiconductors Expectations Ahead Of Q1 Earnings</a>
Outlook: NXP expects second-quarter revenue of $2.8 billion to $3 billion versus estimates of $2.87 billion. The company sees second-quarter adjusted earnings in the range of $2.46 to $2.86 per share versus estimates of $2.65 per share.
The quarterly figures and second-quarter guidance appear to be largely in line with estimates. Cautious commentary from executives as well as a CEO transition appear to be weighing on shares after the bell. 
NXP announced that Sievers intends to retire at the end of 2025. The board has unanimously approved Rafael Sotomayor to succeed Sievers. Sotomayor will take over as president and CEO in October following a transition period.
NXP executives will further discuss the quarter on a call with analysts and investors Tuesday morning at 8 a.m. ET.
NXPI Price Action: <a href="https://www.benzinga.com/quote/NXPI" target="_blank" rel="noreferrer noopener">NXP Semiconductors shares</a> were down 8.02% after-hours, trading at $180.50 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">How You&#8217;ll Know When Tariff Troubles Are Finally Over</a></li>
</ul>
Photo: Lukassek/Shutterstock.

Guidance

Management

NXPI

NXP Semiconductors Reports Q1 Earnings: 'Very Uncertain' Operating Environment Tied To Tariffs, CEO Transition, Shares Fall

<ul>
<li>Reflects business philosophy of commercial success through patient accessibility</li>
<li>Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company's dedicated R&amp;D and manufacturing facility; no impact on shareholder equity</li>
</ul>
WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jSbvQBvaGIm4QLP6v08YeTss46FD6iNPmKu1voOrF5vXBpzNT7keXDuzL599zfMXevkmSVtVucFZru53B0ZvFw==">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. The forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Tevogen Reaffirms Its Top-Line Revenue Forecast For Its Oncology Pipeline, Projecting $1B In Revenue In Its Launch Year And A Cumulative 5-Year Estimate Of Between $10B-$14B

Earnings Beats

ALRS

Alerus Finl Q1 Adj. EPS $0.52 Beats $0.42 Estimate, Sales $68.83M Beat $66.16M Estimate

Biotech

ARTV

Artiva Biotherapeutics to Reveal Longer-term Phase 1/2 Data For AlloNK in Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At the ASGCT 28th Annual Meeting

COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) narrows FY2025 FFO guidance from $2.62-$2.70 to $2.63-$2.69 vs $2.66 analyst estimate..

COPT Defense Props Narrows FY2025 FFO Guidance from $2.62-$2.70 to $2.63-$2.69 vs $2.66 Est

COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) is looking for Q2 FFO of $0.65-$0.67 vs $0.67 analyst estimate..

COPT Defense Props Sees Q2 FFO $0.65-$0.67 vs $0.67 Est

COPT Defense (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 4.84 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $187.86 million which beat the analyst consensus estimate of $175.86 million by 6.82 percent. This is a 2.80 percent decrease over sales of $193.27 million the same period last year.

COPT Defense Q1 FFO $0.65, Inline, Sales $187.86M Beat $175.86M Estimate

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.64 by 20.31 percent. This is a 77.75 percent decrease over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $7.83 billion which beat the analyst consensus estimate of $7.23 billion by 8.29 percent. This is a 3.77 percent decrease over sales of $8.14 billion the same period last year.

Nucor Q1 Adj. EPS $0.77 Beats $0.64 Estimate, Sales $7.83B Beat $7.23B Estimate

ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.95) by 15.79 percent. This is a 25.23 percent increase over losses of $(1.07) per share from the same period last year.

ITOS

ITeos Therapeutics Q1 EPS $(0.80) Beats $(0.95) Estimate

ACET

Adicet Bio To Give Oral Presentation For Its Preclinical ADI-270 Data At The American Society Of Gene And Cell Therapy 28th Annual Meeting

Bitcoin (<a href="https://www.benzinga.com/quote/BTC-USD">BTC</a>) might not be digital gold due to its risky nature. But as an investment over the last 12 months, it's up 49% while the SPDR Gold Trust (<a href="https://www.benzinga.com/quote/GLD">GLD</a>) ETF is up 43%. Nasdaq is up around 8%. Looked at in that time frame, BTC is as good as gold, for real.
"While bitcoin continues to function as an ultra risk-on asset, paradoxically, the digital gold narrative has continued to gather strength," said Greg Waisman, Chief Operating Officer at Mercuryo, a fintech company headquartered in Canada.&nbsp;
"Bitcoin has displayed relative resilience against tariff concerns and a potential recession," he said, noting that BTC has outperformed tech stocks all year. "That might make Bitcoin seen by some as displaying characteristics more akin to a store of value such as gold," Waisman said.
The notion that Bitcoin was "as good as gold" began around 2021. Michael Novogratz, founding CEO of Galaxy Digital Holdings (<a href="https://www.benzinga.com/quote/BRPHF">BRPHF</a>), a crypto investment firm that trades on the Toronto Stock Exchange, <a href="https://www.goldmansachs.com/pdfs/insights/pages/crypto-a-new-asset-class-f/report.pdf?utm">said</a> at the time that "Bitcoin is a really convenient way to store value. The main reason everyone got into bitcoin is the same reason they got into gold—the current macro backdrop is tailor-made for it."
Novogratz later called it <a href="https://www.goldmansachs.com/insights/articles/from_briefings_18-feb-2021?utm">"digital gold"</a> during a Goldman Sachs event that same year. That theme has stuck around ever since.&nbsp;
"The digital gold label reflects Bitcoin's core proposition: scarcity, decentralization, and its role as a store of value," said Mithil Thakore, Co-Founder &amp; CEO at <a href="https://www.benzinga.com/quote/VELAR-USD">Velar</a>, a Dubai-based DeFi play.
If Bitcoin is to be likened as digital gold for its store of value, then it must be seen as the more rambunctious cousin to the yellow metal. Looked at over the last year and Bitcoin looks exactly like gold when compared to GLD. Looked at over five years and Bitcoin is a runaway train, far outpacing everything in the market, with the possible exception of Nvidia (<a href="https://www.benzinga.com/quote/NVDA">NVDA</a>) stocks. Over the last three months, Bitcoin is down 10.7%, but that's better than the Nasdaq. And it has also held its value more than Nvidia.
Gold Safer Bitcoin Since Trump, But Bitcoin Safer Bet Than The S&amp;P 500
Despite Bitcoin being beaten by gold during the recent volatility, it's done better than the S&amp;P 500. Investors lost more money holding the SPDR S&amp;P 500 (<a href="https://www.benzinga.com/quote/SPY">SPY</a>) than they lost in BTC.
In official circles, of course, Bitcoin is not digital gold. The Securities and Exchange Commission <a href="https://www.sec.gov/comments/sr-cboebzx-2021-019/srcboebzx2021019-8857582-239811.pdf?utm">makes it clear</a> to investors: don't get your wires crossed on this trade.&nbsp;
Unlike gold, Bitcoin is not a collateral currency. Central banks hold gold because it can be a ready source of foreign exchange, especially for dollars. Gold can also serve as a collateral to access dollars during a crisis. That's why gold has value because of its repeated historical pattern acting as insurance to access liquidity during times of extreme crisis. As of now, Bitcoin has yet to demonstrate the role as a collateral currency, let alone for central banks.
Earlier this month, Peter Schiff panned the idea of Bitcoin as a safe haven investment. He was mostly criticizing the Trump administration's plan to consider holding BTC in a strategic reserve fund.
"I mean, if it's digital gold, it should have something in common with gold. It should trade similarly to Gold. It should have some kind of positive correlation. It doesn't have any," Schiff <a href="https://www.benzinga.com/25/04/44580634/bitcoin-is-digital-risk-not-digital-gold-asserts-peter-schiff">said</a> during his YouTube podcast. He called it the "anti-gold."&nbsp;
"Bitcoin is more than just a passive hedge," said Thakore. "Unlike gold, which sits in vaults, Bitcoin is programmable and forms the backbone of a new financial system." At Velar, Thakore said he is saying a shift from passive holding of Bitcoin in digital wallets, to active utility as a currency.&nbsp;
"Yes, Bitcoin is way more volatile than gold will ever be, but that volatility also reflects its growth phase," Thakore said. Gold has been around for thousands of years.&nbsp; Bitcoin was created in 2009. "We're witnessing the monetization of the number one digital asset in real time," he said.&nbsp; "In that sense, Bitcoin is gold with a built-in accelerator."
Disclosure: The writer of this article is a Bitcoin investor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Opinion

Bitcoin Might Not Be As Good As Gold Yet, But This Year, It Sure Is Acting Like It

Cellectis (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN&#xAE;-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans.

CLLS

Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) ("the Company"), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.
Oral Presentation Details:
Title: Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model Session: AAV Preclinical and Proof-of-Concept Studies Date and Time: Saturday, May 17, 2025, 9:15 a.m. – 9:30 a.m. CT Location: NOLA Theater A
The presentation will be available via the <a href="https://www.globenewswire.com/Tracker?data=aacUCQgF_Oqe0d8e_y3hmsG1Yc1wJ8J7vtDGrOFywijpE8bvkVPkvuBFk2XlW5vg7tSmk1RCOaeYE2GPEfH0QP9VxkDuoOvEvNpyCBVlpXesQo6kwqP-UmcEIaAmBw0khOcq05KG28BH3sebErxYrKb8bPbMDb5NILxzEUHB5dc=">Presentations &amp; Publications</a> section of the Fractyl website once it concludes on May 17, 2025. &nbsp;

GUTS

Fractyl Health Announces It Will Present Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform At American Society Of Gene And Cell Therapy 2025 Annual Meeting May 13-17, 2025, In New Orleans, Louisiana.

Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/04/b45051710/beyond-inc-delivers-significant-financial-improvement-across-key-operational-guideposts-signals-im">details from the report.&nbsp;</a>
The Details:&nbsp;Beyond reported quarterly losses of&nbsp;42 cents per share, which beat the analyst consensus estimate of&nbsp;losses of 54 cents. Quarterly revenue came in at $231.75 million,&nbsp;which missed the analyst consensus estimate of&nbsp;$288.15 million&nbsp;and is a&nbsp;decrease from revenue of&nbsp;$382.28 million&nbsp;from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Beyond reported: 
<ul>
<li>Gross profit of $58 million, or 25.1% of net revenue, a 560 bps improvement year-over-year. </li>
<li>Sales &amp; Marketing expense of $31 million, or 13.5% of net revenue, a 430 bps improvement year-over-year. </li>
<li>Technology and G&amp;A expense of $41 million vs $50 million in 2024, a $9 million improvement year-over-year. </li>
</ul>
&#8220;While the previously disclosed decision to eliminate non-contributory SKUs and vendors led to lower revenue, we are steadfast in building a more stable foundation for profitability and growth. The sequential improvements we&#8217;ve seen —particularly in gross margin expansion and fixed cost reductions — underscore the intensity I expect in restoring the financial discipline critical to building a profitable growing business,&#8221; said Adrianne Lee, CFO of Beyond.
Outlook:&nbsp;The company said it believes it is 60 days out from transitioning from restructuring to revenue growth. 
BYON Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Beyond stock was up 22.01% after-hours at $5.03 at publication on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

BYON

Beyond Stock Rallies After Q1 EPS Beat Estimates: Details

Events

SGMO

Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17

Press Releases

Credo Schedules Third Quarter Fiscal Year 2025 Financial Results Conference Call

Credo's PCIe® Retimer Successfully Passes PCI-SIG® Compliance

Credo Reports Third Quarter of Fiscal Year 2025 Financial Results

Credo Showcasing AEC PCIe Products for AI Scaling at NVIDIA GTC 2025

Credo Files AEC Patent Infringement Complaint Against Amphenol, Molex, TE Connectivity, and Volex with United States International Trade Commission

Credo and XConn to Showcase Seamless GPU Cluster at NVIDIA GTC

WPG Americas Accelerates High-Speed Connectivity Solutions through Credo Partnership

Credo to Showcase AI Scale Out Fabric Featuring Credo Optical DSPs at OFC 2025

Credo Named a Winner of the 2025 Top Workplaces USA Award

Credo Unveils the Lark Family - Setting a New Benchmark for Low-Power 800G Optical DSPs

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

ASE Technology Holding Co

Broadcom

First Solar

GLOBALFOUNDRIES

Intel

Lattice Semiconductor Corporation - Common Stock

Lattice Semiconductor

Microchip Technology Incorporated - Common Stock

Microchip Technology

Monolithic Power Systems, Inc. - Common Stock

Monolithic Power Systems

Marvell Tech

MACOM Technology Solutions Holdings, Inc. - Common Stock

MACOM Technology Solns

Micron Technology

NVIDIA

Universal Display Corporation - Common Stock

Universal Display

ON Semiconductor Corporation - Common Stock

ON Semiconductor

Qualcomm

Qorvo

STMicroelectronics

Skyworks Solutions

Taiwan Semiconductor Manufacturing Company Ltd.

Taiwan Semiconductor

Texas Instruments Incorporated - Common Stock

Texas Instruments

United Microelectronics Corporation (NEW) Common Stock

United Microelectronics

Barclays

Stifel

Mizuho

Susquehanna

B of A Securities

화요일(4일) 미국 증시는 도널드 트럼프 대통령의 주요 무역 파트너에 대한 관세가 발효되면서 글로벌 무역 긴장이 심화됨에 따라 <a href="https://in.benzinga.com/25/03/44118620/whats-driving-markets-tuesday" target="_blank" rel="noopener">하락했다</a>. 다우존스 산업평균지수는 1.55% 하락한 42,520.99포인트, S&amp;P 500 지수는 1.22% 하락한 5,778.15포인트를 기록했다. 나스닥 종합지수는 0.35% 하락한 18,285.16포인트로 조정 영역에 근접했다.
전반적인 시장 침체에도 불구하고 일부 종목은 하루 종일 개인 트레이더와 투자자들의 관심을 끌었다. 화요일에 소매 투자자와 트레이더의 관심을 받은 주요 주식은 다음과 같다.
<h3>스트레티지 (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>)</h3>
화요일 스트레티지 주식은 9.66% 상승하여 275.15달러에 마감했다. 장중 최고가는 293.04달러, 최저가는 237.01달러였다. 52주 최고가는 542.99달러, 최저가는 101달러다. 최근 비트코인 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 보유량을 유지한다고 밝히고, 우선주에 대한 <a href="https://www.benzinga.com/markets/25/03/44101532/mstr-retains-bitcoin-declares-preferred-dividend-as-michael-saylor-predicts-200-trillion-market-cap-for-bitcoin" target="_blank" rel="noopener">분기별 현금 배당</a>을 발표했다.
<h3>크라우드스트라이크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</h3>
크라우드스트라이크 주식은 1.94% 상승하여 390.16달러에 마감했다. 장중 최고가는 396.16달러, 최저가는 370.58달러였으며, 52주 최고가는 455.44달러, 최저가는 200.81달러다. 회사는 <a href="https://in.benzinga.com/news/earnings/25/03/44127302/crowdstrike-q4-earnings-revenue-beat-eps-beat-strong-momentum-shares-slide-on-soft-guidance" target="_blank" rel="noopener">4분기 실적에서 매출과 주당순이익(EPS)을 초과 달성</a>했다고 보고하여 강력한 모멘텀을 보여주었다. 4분기 매출은 10억 5800만 달러로, 컨센서스 추정치인 10억 3200만 달러를 초과했다.
<h3>베스트바이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</h3>
베스트바이 주식은 13.30% 하락하여 75.20달러에 마감했다. 장중 최고가는 80.13달러, 최저가는 72.92달러였으며, 52주 최고가는 103.71달러, 최저가는 69.29달러다. 코리 배리 CEO는 관세 시행으로 <a href="https://www.benzinga.com/25/03/44115834/best-buy-ceo-says-price-hikes-highly-likely-as-tariffs-take-effect" target="_blank" rel="noopener">가격 인상이 발생할 가능성이 높다고 경고했다.</a> 그는 중국과 멕시코가 베스트바이의 두 주요 공급원이라고 말했다.
<h3>크레도 테크놀로지 그룹 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)</h3>
크레도 테크놀로지 주식은 7.74% 상승하여 54.32달러에 마감했다. 장중 최고가는 55.87달러, 최저가는 48.40달러였으며, 52주 최고가는 86.69달러, 최저가는 16.82달러다. 회사는 <a href="https://in.benzinga.com/news/earnings/25/03/44127539/credo-technology-stock-rallies-after-better-than-expected-q3-report-details" target="_blank" rel="noopener">예상보다 좋은 3분기 실적</a>을 발표하여 주가가 상승했다. 주당순이익은 25센트로, 컨센서스 추정치인 18센트를 초과했다.
<h3>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</h3>
테슬라 주식은 4.43% 하락하여 272.04달러에 마감했다. 장중 최고가는 284.35달러, 최저가는 261.84달러였으며, 52주 최고가는 488.54달러, 최저가는 138.80달러다. 회사의 중국산 전기차 판매가 2월에 감소하여 주식이 하락했다. 중국승용차협회에 따르면 테슬라는 2월에 30,688대의 중국산 전기차를 판매했으며, 이는 전년 대비 49.2% 감소한 수치다.
이미지 출처: Shutterstock
<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 크레도 테크놀로지 그룹 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) 주식은 2분기 실적 발표 후 주가가 51.61% 급등하였으며, 여러 회사들이 주식에 대한 <a href="https://www.benzinga.com//node/42298407" target="_blank" rel="noreferrer noopener">가격 예측을 상향 조정</a>했다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) 주식은 내부 조사 결과 <a href="https://www.benzinga.com//node/42367077" target="_blank" rel="noreferrer noopener">경영진이나 이사회와 관련</a>된 &#8220;불법 행위나 사기 증거가 없다&#8221;는 발표 후 34.59% 상승했다.
3. 도큐사인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) 주식은 3분기 실적 발표 및 <a href="https://www.benzinga.com//node/42352653" target="_blank" rel="noreferrer noopener">기대보다 좋은 가이던스 발표</a> 이후 34.26% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/docu/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 상향 조정</a>했다.
4. 루브릭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) 주식은 3분기 실적이 기대 이상으로 나타난 후 <a href="https://www.benzinga.com//node/42353379" target="_blank" rel="noreferrer noopener">주가가 27.17% 상승</a>했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/rbrk/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 상향 조정</a>했다.
5. 룰루레몬 애틀라티카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) 주식은 3분기 실적이 기대 이상으로 나타난 후 주가가 24.62% 상승했으며, <a href="https://www.benzinga.com//node/42367217" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 예측을 상향 조정</a>했다.
6. 퓨어 스토리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) 주식은 3분기 재무 실적이 기대 이상으로 나타나고 <a href="https://www.benzinga.com//node/42303442" target="_blank" rel="noreferrer noopener">4분기 가이던스 발표</a> 이후 22.51% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/pstg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 상향 조정</a>했다.
7. 마벨 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) 주식은 3분기 실적이 긍정적으로 나타나고 <a href="https://www.benzinga.com//node/42321281" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 예측을 상향 조정</a>한 후 22.46% 상승했다.
8. 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) 주식은 애널리스트의 긍정적인 평가로 주가가 21.86% 상승했다. 니덤(Needham)이 &#8220;매수&#8221; 등급을 유지하고 <a href="https://www.benzinga.com//node/42325582" target="_blank" rel="noreferrer noopener">100달러 목표 주가를 재확인</a>했다.
9. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) 주식은 지난주 21.33% 상승했다.
10. 아메리칸 항공 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) 주식은 4분기 및 연간 전망이 기대 이상으로 나타난 후 19.83% 상승했다.
11. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) 주식은 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42324175" target="_blank" rel="noreferrer noopener">가격 예측을 상향 조정</a>한 후 19.23% 상승했다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

크레도 테크놀로지 그룹 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)가 월요일에 예상치를 크게 상회하는 2025회계연도 2분기 재무 실적을 발표한 후 화요일(3일) 주가는 급등했다. <a href="//www.benzinga.com/quote/CRDO/news"" target="_blank" rel="noopener">알아 두어야 할 내용</a>은 다음과 같다.
알아야 할 내용: 월요일(2일) 크레도 테크놀로지는 전기 대비 21%, 전년 동기 대비 64% 증가한 7,200만 달러의 매출을 보고하며 컨센서스 예상치 6,678만 9,000달러를 초과했다.  조정 주당순이익은 7센트로 컨센서스 예상치 5센트를 40% 상회했다.
일반회계기준(GAAP) 매출총이익률은 63.2%, 비일반회계기준(Non-GAAP) 매출총이익률 63.6%를 달성했다. 또한, 크레도는 3억 8,300만 달러의 현금 및 단기 투자를 보고했다.
앞으로 크레도는 1억 1,500만 달러~1억 2,500만 달러 범위 매출을 예상하여 애널리스트의 이전 예상치인 8,604만 달러보다 높은 전망을 발표했다. 비일반회계기준 매출총이익률은 61.0%~63.0%, 통제된 운영 비용은 4,200만 달러~4,400만 달러를 유지할 것으로 예상했다.
크레도 테크놀로지 CEO인 빌 브레넌(Bill Brennan)은 빠르게 성장하는 AI 및 데이터 인프라 시장 내에서 전략적 포지셔닝을 크레도의 성공 요인으로 꼽았다. 그는 2분기에 제품 수요가 예상치를 뛰어넘는 등 전환점이 되었다고 언급했다. 이러한 성장은 AI 배포를 가속화하고 고객 관계를 강화한 데 힘입은 결과다.
애널리스트 업데이트: 뱅크오브아메리카증권은 크레도 목표주가를 27달러에서 80달러로 올리고 주식을 &#8216;매수&#8217; 의견으로 상향 조정했다. 바클레이즈도 뒤따라 목표주가를 80달러로 올렸고, 니덤은 목표주가를 43달러에서 70달러로 올렸다.
크레도 주가 움직임: <a href="//pro.benzinga.com/dashboard"" target="_blank" rel="noopener">벤징가 프로</a>에 따르면 크레도의 화요일 주가는 47.89% 상승한 70.69달러로 마감했다.
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" class="wp-image-675156" style="width: 530px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03140055/Screenshot-2024-12-03-140030-1024x535.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03140055/Screenshot-2024-12-03-140030-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03140055/Screenshot-2024-12-03-140030-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03140055/Screenshot-2024-12-03-140030-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03140055/Screenshot-2024-12-03-140030.png 1165w" alt="" width="1024" height="535" /></a></figure>
이미지 출처: Credosemi
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일(2일) 아침 미국 주식 선물이 하락세를 보이는 가운데 오늘 투자자들이 주목할 만한 종목은 다음과 같다.
1. 임페리얼 페트롤리엄 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPP#NASDAQ">IMPP</a>)
임페리얼 페트롤리엄의 분기 실적은 주당순이익 26센트, 매출 3,580만 달러로 예상된다. 주가는 시간외 거래에서 0.6% 상승한 3.20달러에 거래되었다.
2. 니오 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)
니오는 11월에 20,575대의 차량을 인도했으며, 이는 전년 대비 28.9% 증가한 수치라고 발표했다. 지난 금요일(29일) 2.3% 상승하여 4.48달러로 마감했다.
3. 지스케일러 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)가
오늘 장 마감 후 실적을 발표하는 지스케일러의 분기 주당순이익은 63센트, 매출은 6억 6,062만 달러로 예상된다. 시간외 거래에서 0.8% 상승한 206.59달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 커버리지</a>를 확인하세요.
4. 샤오펑 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)
샤오펑은 11월에 30,895대의 스마트 전기차를 인도했으며, 이는 전년 대비 54% 증가하고 전월 대비 29% 증가한 수치라고 보고했다. 시간외 거래에서 0.1% 하락한 12.05달러에 거래되었다.
5. 크레도 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)
크레도 테크놀로지의 분기 주당순이익은 5센트, 매출은 6,679만 달러로 예상된다. 주식은 시간외 거래에서 1.9% 상승한 49.90달러에 거래되었다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Pre-Market Outlook

IMPP

XPEV

월요일 주목해야 할 주식: 임페리얼 페트롤리엄, 지스케일러, 니오, 샤오펑 및 크레도

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
1. 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">캐나다의 다양한 금융 옵션</a>에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)가 <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 재무 결과</a>를 보고한 후 주가는 32.04% 상승했다.
3. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)가 <a href="https://www.benzinga.com/pressreleases/24/08/g40481411/procept-biorobotics-announces-fda-clearance-of-the-hydros-robotic-system-the-next-generation-ai-po" target="_blank" rel="noopener">자사의 하이드로스 로보틱(HYDROS Robotic) 시스템</a>에 대한 FDA 510(k) 승인을 발표한 후 주가는 22.67% 상승했다.
4. 크레도 테크놀로지 그룹 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)의 주식이 20.02% 상승했다.
5. 에볼런트 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>)가 <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매각을 모색하고</a> 있다는 보고서가 나온 후 주가는 19.98% 상승했다.
6. 그리폴스 S.A.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) 주식이 19.50% 급등했다. 이는 브룩필드 에셋 매니지먼트(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/bam" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BAM" data-google-interstitial="false">BAM</a>)가 회사를 인수하기 위해 부채 자금을 모색하고 있다는 보도가 나온 후 발생한 일이다.
7. 뉴발런트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>)의 주식이 19.33% 상승했다.
8. 에이머 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>)가 예상보다 나은 2분기 <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">실적을 보고하고 FY24 EPS 전망을 상향</a> 조정한 후 주식이 16.60% 급등했다.
추가로 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%a4%8c-%eb%b9%84%eb%94%94%ec%98%a4-%eb%b0%8f-%ed%83%80%ea%b9%83%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-11%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">줌 비디오 및 타깃은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%8a%a4%eb%85%b8%ec%9a%b0%ed%94%8c%eb%a0%88%ec%9d%b4%ed%81%ac-%eb%b0%8f-jd%eb%8b%b7%ec%bb%b4-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-8/" target="_blank" rel="noopener">스노우플레이크 및 JD닷컴 지난주 최악의 성과를 보인 8개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Credo Technology Group

뉴스

에 대한 최신 뉴스 Credo Technology Group (NASDAQ:CRDO) 주식

수요일, 3월 05, 2025

일요일, 12월 08, 2024

화요일, 12월 03, 2024

월요일, 12월 02, 2024

일요일, 8월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌